Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)
NCT01445873
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Idiopathic PAH, or PAH secondary to connective tissue disease
- Receipt of Thelin for treatment of PAH
- 6 months of follow-up (except in the event of death) subsequent to initial receipt of Thelin
- Minimum of one clinic visit documented in the medical record during the 6-month period subsequent to initial receipt of Thelin
- Participation in any investigational study of Thelin or any other medication for the
treatment of PAH during the period beginning 6 months prior to initial receipt of
Thelin and ending 6 months subsequent to such receipt
- Receipt of Thelin prior to January 11, 2005 (i.e., the date following the last day on
which patients could be enrolled in double-blind treatment in STRIDE-1, STRIDE-2,
and/or STRIDE-6); or
- Known contraindications to Thelin therapy (i.e., known hypersensitivity to sitaxsentan
or any of its excipients; mild-to-severe hepatic impairment [Child-Pugh Class A-C];
elevated aminotransferases prior to initiation of treatment, defined as aspartate
aminotransferase [AST] and/or alanine aminotransferase [ALT] >3 times upper limit of
normal [ULN]; concomitant use of cyclosporin A; lactation)
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Hyderabad, Andra Pradesh
- Ahmedabad, Gujarat
- Vadodara, Gujarat
- Bangalore, Karnataka
- Noida, Uttar Pradesh
- Los Angeles, California
- Detroit, Michigan
- Pittsburgh, Pennsylvania
- Houston, Texas
- Houston, Texas
- San Antonio, Texas
- Darlinghurst, New South Wales
- Chermside, Queensland
- Praha 2,
- Praha 4,
- Lille,
- Lille,
- Vandoeuvre Les Nancy,
- Berlin,
- Coburg,
- Essen,
- Giessen,
- Hannover,
- Homburg,
- Leipzig,
- Muenchen,
- Nuernberg,
- Wuerzburg,
- Haidari, Athens
- Haifa,
- Petach Tikva,
- Napoli,
- Roma,
- Taipei,
- Papworth Everard, Cambridgeshire
- Phoenix, Arizona
- Augusta, Georgia
- Decatur, Georgia
- Elk Grove Village, Illinois
- Indianapolis, Indiana
- Chapel Hill, North Carolina
- Charlotte, North Carolina
- Houston, Texas
- Salt Lake City, Utah
- Richmond, Virginia
- Richmond, Virginia
- Leuven,
- Porto Alegre, RS
- Sao Paulo, SP
- Sofia,
- Sofia,
- Beijing,
- Shanghai,
- Haidari, Athens
- Hyderabad, Andhra Pradesh
- Ahmedabad, Gujarat
- Vadodara, Gujarat
- Bangalore, Karnataka
- Noida, Uttar Pradesh
- Pavia,
- Roma,
- Riga,
- Kuala Lumpur,
- Amsterdam,
- Rotterdam,
- Manila City,
- Quezon City,
- Krakow,
- Zabrze,
- Timisoara, Timis
- Iasi,
- Moscow,
- Moscow,
- Amphoe Mueang, Khon Kaen
- Bangkok,
- Norwich, Norfolk
- Newcastle Upon Tyne, Tyne and Wear
| Descriptive Information | |||||
|---|---|---|---|---|---|
| Brief Title | Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH) | ||||
| Official Title | NON-INTERVENTIONAL (NI) DRUG STUDY PROTOCOL: THREE-COUNTRY PILOT STUDY FOR RETROSPECTIVE CHART REVIEW OF EFFECTIVENESS OF THELIN® (SITAXSENTAN) IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) | ||||
| Brief Summary | The objectives of this study are to develop research methods and corresponding materials for a study of the effectiveness of sitaxentan sodium (Thelin) in "real-world" settings; to pilot test these methods at three study centers in Europe; and to refine and finalize research methods and corresponding materials for possible use in a follow-on, full-scale examination of the effectiveness of sitaxentan sodium (Thelin) in "real-world" settings. | ||||
| Detailed Description | At each centre, approximately 12-15 Pulmonary Arterial Hypertension (PAH) consecutive patients who have received Thelin and who meet all other study entry criteria. | ||||
| Study Type | Observational | ||||
| Study Design | Observational Model: Cohort Time Perspective: Retrospective | ||||
| Target Follow-Up Duration | Not Provided | ||||
| Biospecimen | Not Provided | ||||
| Sampling Method | Non-Probability Sample | ||||
| Study Population | Patients with Pulmonary Arterial Hypertension (PAH) (Idiopathic or secondary to connective tissue disease), receiving sitaxentan sodium (Thelin) for treatment of their PAH for at least 6 months. | ||||
| Condition | Pulmonary Arterial Hypertension | ||||
| Intervention | Drug: Sitaxentan sodium
Sitaxentan sodium 100 mg / day | ||||
| Study Groups/Cohorts | PAH patients receiving Sitaxentan
Intervention: Drug: Sitaxentan sodium | ||||
| Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
| Recruitment Information | |||||
| Recruitment Status | Completed | ||||
| Actual Enrollment | 36 | ||||
| Original Actual Enrollment | Same as current | ||||
| Actual Study Completion Date | March 28, 2011 | ||||
| Actual Primary Completion Date | March 28, 2011 (Final data collection date for primary outcome measure) | ||||
| Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
| ||||
| Sex/Gender |
| ||||
| Ages | 18 Years and older (Adult, Older Adult) | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts | Contact information is only displayed when the study is recruiting subjects | ||||
| Listed Location Countries | Not Provided | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT01445873 | ||||
| Other Study ID Numbers | B1321051 | ||||
| Has Data Monitoring Committee | No | ||||
| U.S. FDA-regulated Product | Not Provided | ||||
| IPD Sharing Statement |
| ||||
| Responsible Party | Pfizer | ||||
| Study Sponsor | Pfizer | ||||
| Collaborators | Not Provided | ||||
| Investigators |
| ||||
| PRS Account | Pfizer | ||||
| Verification Date | August 2020 | ||||